by Jordana Choucair | Dec 17, 2021 | Life Sciences
The CDC has changed its recommendations for COVID-19 vaccines to clarify that mRNA vaccines are the preferred option over the Johnson & Johnson (J&J) vaccine. Although some members of the CDC advisory committee said the J&J vaccine should remain available...
by Jordana Choucair | Dec 16, 2021 | Life Sciences
A preliminary study found that two doses of the Moderna COVID-19 vaccine are less effective at neutralizing the omicron variant. The study, which examined the antibodies in blood samples from 30 people who had gotten two Moderna shots are, found that antibodies in...
by Jordana Choucair | Dec 14, 2021 | Life Sciences
A two-shot course of the Pfizer-BioNTech COVID-19 vaccination may offer 70 percent protection against being hospitalized with the omicron variant. According to Discovery Ltd., South Africa’s largest medical-insurance provider, the protection is maintained across age...
by Jordana Choucair | Dec 14, 2021 | Life Sciences
Pfizer released new data confirming its oral antiviral pill for COVID-19 reduced the risk of hospitalization or death by 89 percent in high-risk adults. The company said there is an ongoing interim analysis of a second study of the pill, called Paxlovid, which has so...
by Jordana Choucair | Dec 13, 2021 | Life Sciences
An Israeli study found that a booster shot of Pfizer/BioNTech COVID-19 vaccine provides good protection against severe illness from the Omicron variant. Conversely, people who got a “second dose of the vaccine five to six months ago don’t have any neutralizing...
by Jordana Choucair | Dec 10, 2021 | Life Sciences
The FDA authorized the Pfizer/BioNTech COVID-19 vaccine booster shots for people ages 16 and 17. Just as with adults, 16- and 17-year-olds are eligible to receive a booster dose six months after their second dose of the Pfizer/BioNTech vaccine. CDC Director Dr....
Recent Comments